Vifor Pharma (LSE:0RPD) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

0RPD Overzicht aandelen

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.

Over het bedrijf

0RPD fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	1/6
Prestaties in het verleden	4/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 8.73% per jaar groeien

De winst groeide het afgelopen jaar met 5.7%

Risicoanalyse

De laatste financiële rapporten zijn ouder dan 6 maanden

Vifor Pharma AG Concurrenten

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

GSK

LSE:GSK

UK£57.4b

HUTCHMED (China)

AIM:HCM

UK£2.5b

AstraZeneca

LSE:AZN

UK£173.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Vifor Pharma
Historische aandelenkoersen
Huidige aandelenkoers	CHF 165.25
52 Week Hoogtepunt	CHF 196.80
52 Week Laag	CHF 157.90
Bèta	1.04
11 maand verandering	-2.40%
3 maanden verandering	-6.73%
1 Jaar Verandering	2.01%
33 jaar verandering	-8.17%
5 jaar verandering	32.20%
Verandering sinds IPO	91.35%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0RPD	GB Pharmaceuticals	GB Markt
7D	0.3%	-4.7%	-1.1%
1Y	2.0%	5.6%	10.2%

Rendement versus industrie: 0RPD presteerde slechter dan de UK Pharmaceuticals -sector, die het afgelopen jaar een rendement van 5.6 % opleverde.

Rendement versus markt: 0RPD overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 10.2 %.

Prijsvolatiliteit

Is 0RPD's price volatile compared to industry and market?
0RPD volatility
0RPD Average Weekly Movement	2.0%
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	9.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0RPD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van 0RPD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1872	2,200	n/a	www.viforpharma.com

Vifor Pharma AG Samenvatting

Hoe verhouden de winst en inkomsten van Vifor Pharma zich tot de beurswaarde?
0RPD fundamentele statistieken
Marktkapitalisatie	CHF 10.78b
Inkomsten(TTM)	CHF 146.60m
Inkomsten(TTM)	CHF 1.81b

73.1x

Koers/Winstverhouding

5.9x

P/S-verhouding

Is 0RPD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0RPD resultatenrekening (TTM)
Inkomsten	CHF 1.81b
Kosten van inkomsten	CHF 671.80m
Brutowinst	CHF 1.14b
Overige uitgaven	CHF 993.70m
Inkomsten	CHF 146.60m

Laatst gerapporteerde inkomsten

Dec 31, 2021

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	2.26
Brutomarge	62.93%
Nettowinstmarge	8.09%
Schuld/Eigen Vermogen Verhouding	13.6%

Hoe presteerde 0RPD op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

0RPD Overzicht aandelen

Beloningen

Risicoanalyse

Vifor Pharma AG Concurrenten

LSE:HIK

UK£4.2b

LSE:GSK

UK£57.4b

AIM:HCM

UK£2.5b

LSE:AZN

UK£173.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

High number of new directors

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Investor sentiment improved over the past week

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Chief Executive Officer Stefan Schulze has left the company

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Independent Director has left the company

Independent Director has left the company

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Upcoming dividend of CHF2.00 per share

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Revenue misses expectations

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

New 90-day low: CHF113

New 90-day low: CHF118

Vifor Pharma Announces Board Changes

New 90-day high: CHF137

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Market bids up stock over the past week

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

New 90-day low: CHF120

New 90-day low: CHF122

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

New 90-day low - CHF124

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

New 90-day low - CHF134

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Vifor Pharma AG Samenvatting

73.1x

5.9x

Inkomsten en omzet